Gaiane M. Rauch, M.D., Ph.D.

Peer-Reviewed Articles

1. Mitchell M, Shaitelman SF, Smith BD, Krishnamurthy S, Valero V, Rauch GM, Shen Y, Lin H, Kuerer HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. EJSO 50(12):108613, 2024. e-Pub 2024. PMID: 39243728.
2. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Combining biology-based and MRI data-driven modeling to predict response to neoadjuvant chemotherapy in patients with triple-negative breast cancer. Radiol Artif Intell None(None):e240124, 2024. e-Pub 2024. PMID: 39503605.
3. Yam C, Patel M, Hill H, Sun R, Bassett R, Kong E, Damodaran S, Koenig K, Abourharb S, Saleem S, Bisen A, Murthy R, Ramirez D, Rauch G, Adrada B, Candelaria R, Wang X, Mittendorf E, Thompson A, White J, Ravenberg E, Clayborn A, Ding QQ, Booser D, Oke O, Brewster A, Hortobagyi G, Ibrahim N, Litton J, Valero V, Tripathy D, Chen K, Korkut A, Moulder S, Huo L, Lim B, Ueno N. Targeting the epidermal growth factor receptor pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study. Cancer Res Comm None(None):None. e-Pub 2024. PMID: 39356138.
4. Christenson C, Ch W, Hormuth DA, Stowers CE, LaMonica M, Ma J, Rauch GM, Yankeelov TE. Fast model calibration for predicting the response of breast cancer to chemotherapy using proper orthogonal decomposition. J Comput Sci None(None):None, 2024. PMID: None.
5. Patel MM, Adrada BE, Guirguis MS, Whitman GJ, Moseley TS, Rauch GM. Current concepts in molecular breast imaging. JBI None(None):None. e-Pub 2024. PMID: None.
6. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Optimizing neoadjuvant chemotherapy regimens via MRI-based digital twins to improve treatment response of triple-negative breast cancer. npj Digital Medicine None(None):None. e-Pub 2024. PMID: None.
7. Golia-Pernicka SJ, Lambregts D, de Oliveira F, Gangai N, Khellaf L, Bates D, Sheedy S, Lee S, Khatri G, Hiram S, Rauch GM, Kaur H, Brown G, Rouanet P, Laborie L, Petkovska I. MRI-based morphological analysis of tumor deposits in rectal cancer: a multicentric study. Diagn Interv Imag None(None):None. e-Pub 2024. PMID: None.
8. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating biology-based and data-driven modeling to predict the response of locally advanced triple-negative breast cancer before initiating neoadjuvant chemotherapy. Radiology: AI None(None):None. e-Pub 2024. PMID: None.
9. Mohamed RM, Panthi B, Adrada BE, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed B, Scoggins ME, Son JB, Thompson A, Tripathy D, Valero V, Wei P, White J, Whitman GJ, Xu Z, Yang W, Yam C, Ma J, Rauch GM. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Sci Rep 14(1):16073, 2024. e-Pub 2024. PMID: 38992094.
10. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett RL, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman RM, Valero V, Tripathy D, Lewis MT, Dobrolecki L, Lei J, Candelaria R, Arun B, Rauch GM, Zhao L, Zhang J, Ding Q, Symmans WF, Thompson A, Moulder S, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into ARness. Cell Rep 5(6):101595, 2024. PMID: 38838676.
11. Expert Panel on GYN, Imaging OB, Shinagare AB, Burk KS, Kilcoyne A, Akin EA, Chuang L, Hindman NM, Huang C, Rauch GM, Small W, Stein EB, Venkatesan AM, Kang SK. ACR Appropriateness Criteria® pretreatment evaluation and follow-up of invasive cancer of the cervix: 2023 update. J Am Coll Radiol 21(6S):S249-S267, 2024. PMID: 38823948.
12. Guirguis MS, Adrada B, Yam C, Tripathy D, Candelaria R, Yang W, Patel M, Moseley T, Perez F, Whitman GJ, Leung JWT, Le-Petross H, Lane DL, Huo L, Litton J, Valero V, Hung KK, Arun B, Mohamed R, Sun J, Korkut A, Xu Z, Pashapoor S, White J, Son JB, Thompson A, Wei P, Ma J, Moulder S, Rauch GM. Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer. JCO None(None):None. e-Pub 2024. PMID: None.
13. Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient interest in exploring non-surgical treatment approaches for early stage breast cancer: A qualitative study. Int J Radiat Oncol Biol Phys 118(2):443-454, 2024. e-Pub 2023. PMID: 37802228.
14. Jacobsen MC, Rigaud B, Simiele SJ, Rauch GM, Ning MS, Vedam S, Klopp AH, Stafford RJ, Brock KK, Venkatesan AM. Feasibility of quantitative diffusion-weighted imaging during intra-procedural MRI-guided brachytherapy of locally advanced cervical and vaginal cancers. Brachytherapy 22(6):736-745, 2023. PMID: 37612174.
15. Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS. Triple-negative breast cancer: histopathologic features, genomics, and treatment. Radiographics 43(10):e230034, 2023. PMID: 37792593.
16. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Study Group ER. Patient-reported outcomes of omission of breast surgery following neoadjuvant systemic therapy: a nonrandomized clinical trial. JAMA Netw Open 6(9):e2333933, 2023. PMID: 37707811.
17. Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GM. A radiomics model based on synthetic MRI acquisition for predicting neoadjuvant systemic treatment response in triple-negative breast cancer. Radiol Imaging Cancer 5(4):e230009, 2023. PMID: 37505106.
18. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive roles of baseline stromal tumor-infiltrating lymphocytes and Ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers (Basel) 15(13):3275, 2023. PMID: 37444385.
19. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: A phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. PMID: 37043123.
20. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. PMID: 37061619.
21. Phillips CM, EABF L, Wu C, Jarrett AM, Zhou Z, Elshafeey N, Ma J, Rauch GM, Yankeelov TE. Assessing the identifiability of model selection frameworks for the prediction of patient outcomes in the clinical breast cancer setting. J Comput Sci 69(None):102006, 2023. e-Pub 2023. PMID: None.
22. Awiwi MO, Kaur H, Ernst R, Rauch GM, Morani AC, Stanietzky N, Palmquist SM, Salem UI. Restaging MRI of rectal adenocarcinoma after neoadjuvant chemoradiotherapy: Imaging findings and potential pitfalls. Radiographics 43(4):e220135, 2023. PMID: 36927125.
23. Shinagare AB, Burk KS, Kilcoyne A, Akin EA, Chuang L, Hindman NM, Huang C, Rauch GM, Small W Stein EN Venkatesan AM, Kang SK. Pretreatment evaluation and follow-up of invasive cancer of the cervix. ACR None(None):None. e-Pub 2023. PMID: None.
24. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Assessment of response to neoadjuvant systemic treatment in triple-negative breast cancer using functional tumor volumes from longitudinal dynamic contrast-enhanced MRI. Cancers (Basel) 15(4):1025, 2023. PMID: 36831368.
25. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep 13(1):1171, 2023. e-Pub 2023. PMID: 36670144.
26. Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer 9(1):2, 2023. e-Pub 2023. PMID: 36627285.
27. Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma J. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol 13, 2023. PMID: 37941561.
28. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15, 2023. PMID: 37547448.
29. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. PMID: 36306810.
30. Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GM. Quantitative apparent diffusion coefficients from peritumoral regions as early predictors of response to neoadjuvant systemic therapy in triple-negative breast cancer. J Magn Reson Imaging 56(6):1901-1909, 2022. PMID: 35499264.
31. Maheshwari E, Nougaret S, Stein EB, Rauch GM, Hwang KP, Stafford RJ, Klopp AH, Soliman PT, Maturen KE, Rockall AG, Lee SI, Sadowski EA, Venkatesan AM. Update on MRI in evaluation and treatment of endometrial cancer. Radiographics 42(7):2112-2130, 2022. PMID: 36018785.
32. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. MRI-based digital models forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. Cancer Res 82(18):3394-3404, 2022. PMID: 35914239.
33. Lopez BP, Rauch GM, Adrada B, Kappadath SC. Functional tumor diameter measurement with Molecular Breast Imaging: Development and clinical application. Biomed Phys Eng Express 8(5), 2022. PMID: 35917778.
34. Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Front Artif Intell 5, 2022. e-Pub 2022. PMID: 36034598.
35. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
36. Jacobsen MC, Beriwal S, Dyer BA, Klopp AH, Lee SI, McGinnis GJ, Robbins JB, Rauch GM, Sadowski EA, Simiele SJ, Stafford RJ, Taunk NK, Yashar CM, Venkatesan AM. Contemporary image-guided cervical cancer brachytherapy: Consensus imaging recommendations from the Society of Abdominal Radiology and the American Brachytherapy Society. Brachytherapy 17(4):369-388, 2022. e-Pub 2022. PMID: 35725550.
37. Hruska, CB, Corion, C, de Geus-Oei, LF, Adrada, BE, Fowler, AM, Hunt, KN, Kappadath, SC, Pilkington, P, Pereira Arias-Bouda, LM, Rauch, GM. SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated g-Cameras. JNMT 50(2):103-110, 2022. PMID: None.
38. Candelaria RP, Adrada BE, Lane DL, Rauch GM, Moulder SL, Thompson AM, Bassett RL, Arribas EM, Le-Petross HT, Leung JWT, Spak DA, Ravenberg EE, White JB, Valero V, Yang WT. Midtreatment ultrasound descriptors as qualitative imaging biomarkers of pathologic complete response in patients with triple negative breast cancer. Ultrasound Med Biol 48(6):1010-1018, 2022. PMID: 35300879.
39. Shinagare AB, Sadowski EA, Park H, Brook OR, Forstner R, Wallace SK, Horowitz JM, Horowitz N, Javitt M, Jha P, Kido A, Lakhman Y, Lee SI, Manganaro L, Maturen KE, Nougaret S, Poder L, Rauch GM, Reinhold C, Sala E, Thomassin-Naggara I, Vargas HA, Venkatesan A, Nikolic O, Rockall AG. Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR uterine and ovarian cancer disease-focused panel and the ESUR female pelvic imaging working group. Eur Radiol 32(5):3220-3235, 2022. PMID: 34846566.
40. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol 149, 2022. PMID: 35193025.
41. Seth S, Sun R, White JB, Ravenberg E, Yam C, Lim B, Litton JK, Tripathy D, Valero V, Damodaran S, Arun B, Ueno NT, Lucci A, Thompson A, Mittendorf E, Rauch GM, Adrada B, Candelaria R, Ding Q, Powell RT, Abuhadra NK, Piwnica-Worms H, Zhang J, Song X, Symmans WF, Huo L, Futreal A, Draetta G, Chang JT, Moulder S. Comprehensive molecular profiling identifies features of disease resistance to neoadjuvant chemotherapy in triple-negative breast cancer. Nature Medicine None(None):None. e-Pub 2022. PMID: None.
42. Guirguis MS, Adrada BE, Scoggins ME, Moseley TW, Dryden MJ, Le-Petross HC, Rauch GM, Whitman GJ. The challenging image-guided preoperative breast localization: A modality-based approach. AJR Am J Roentgenol 218(3):423-434, 2022. PMID: 34612680.
43. Adrada BE, Guirguis MS, Hoang T, Spak DA, Rauch GM, Moseley TW. MRI-guided breast biopsy case-based review: Essential techniques and approaches for success with challenging cases. Radiographics 42(2):E46-E47, 2022. PMID: 35119965.
44. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5), 2022. PMID: 35267631.
45. Guirguis MS, Checka C, Adrada BE, Whitman GJ, Dryden MJ, Sun J, Ding QQ, Le-Petross H, Rauch GM, Clemens M, Moseley TW. Bracketing with multiple radioactive seeds to achieve negative margins in breast conservation surgery: multiple seeds in breast surgery. Clin Breast Cancer 22(2):e158-e166, 2022. PMID: 34187752.
46. Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WT. BI-RADS ultrasound lexicon descriptors and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer. Acad Radiol 29 Suppl 1:S35-S41, 2022. PMID: 34272161.
47. Covington MF, Parent EE, Dibble EH, Rauch GM, Fowler AM. Advances and future directions in Molecular Breast Imaging. J Nucl Med 63(1):17-21, 2022. e-Pub 2021. PMID: 34887334.
48. Adrada BE, Karbasian N, Huang M, Rauch GM, Woodtichartpreecha P, Whitman G. Imaging surveillance of the reconstructed breast in a subset of patients may aid in early detection of breast cancer recurrence. J Clin Imaging Sci 11:58, 2021. e-Pub 2021. PMID: 34877066.
49. Expert Panel on GYN, Imaging OB, Kilcoyne A, Gottumukkala RV, Kang SK, Akin EA, Hauck C, Hindman NM, Huang C, Khanna N, Paspulati R, Rauch GM, Said T, Shinagare AB, Stein EB, Venkatesan AM, Maturen KE. ACR Appropriateness Criteria® staging and follow-up of primary vaginal cancer. J Am Coll Radiol 18(11S):S442-S455, 2021. PMID: 34794599.
50. Yam C, Yen EY, Chang JT, Bassett RL, Al-Atrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder-Thompson S, Mittendorf EA. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
51. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Ma J, Pagel MD. Assessment of early response to neoadjuvant systemic therapy in triple-negative breast cancer using amide proton transfer-weighted chemical exchange saturation transfer MRI: A pilot study. Radiol Imaging Cancer 3(5):e200155, 2021. PMID: 34477453.
52. Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GM. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer 127(16):2880-2887, 2021. PMID: 33878210.
53. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging 54(1):251-260, 2021. PMID: 33586845.
54. Lopez BP, Guan F, Rauch GM, Kappadath SC. Monte Carlo simulation of pixelated CZT detector with Geant4: Validation of clinical molecular breast imaging system. Phys Med Biol 66(12), 2021. PMID: 34038878.
55. Expert Panel on GYN, Imaging OB, Lakhman Y, Vargas HA, Reinhold C, Akin EA, Bhosale PR, Huang C, Kang SK, Khanna N, Kilcoyne A, Nicola R, Paspulati R, Rauch GM, Shinagare AB, Small W, Glanc P. ACR Appropriateness Criteria® Staging and follow-up of primary vulvar cancer. J Am Coll Radiol 18(5):S212-S228, 2021. PMID: 33958115.
56. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. PMID: 32984932.
57. Bragg A, Candelaria R, Adrada B, Huang M, Rauch G, Santiago L, Scoggins M, Whitman G. Imaging of noncalcified ductal carcinoma in situ. J Clin Imaging Sci 11:34, 2021. PMID: 34221643.
58. Pfob A, Sidey-Gibbons C, Lee HB, Tasoulis MK, Koelbel V, Golatta M, Rauch GM, Smith BD, Valero V, Han W, MacNeill F, Weber WP, Rauch G, Kuerer HM, Heil J. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer 143:134-146, 2021. PMID: 33307491.
59. Kuerer HM, Gibbons C, Rauch GM, Smith B, Valero V, MacNeill F, Weber W, Rauch G, Heil J, Golatta M, Kolbel V. De-escalation of surgical therapy: What does the data support?. EJC None(None):None. e-Pub 2020. PMID: None.
60. Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, Yang WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol 130(None):109170, 2020. e-Pub 2020. PMID: 32777736.
61. Ning MS, Venkatesan AM, Stafford RJ, Bui TP, Carlson R, Bailard NS, Vedam S, Davis R, Olivieri ND, Guzman AB, Incalcaterra JR, McKelvey FA, Thaker NG, Rauch GM, Tang C, Frank SJ, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: methods, process workflow, and value-based analysis. Brachytherapy 19(4):427-437, 2020. e-Pub 2019. PMID: 31786169.
62. Rauch G, Ueno N, Le-Petross HC. Inflammatory breast cancer. RSNA Case Collection. e-Pub 2020. PMID: None.
63. Hope TA, Gollub MJ, Arya S, Bates DDB, Ganeshan D, Harisinghani M, Jhaveri KS, Kassam Z, Kim DH, Korngold E, Lalwani N, Moreno CC, Nougaret S, Paroder V, Paspulati RM, Golia Pernicka JS, Petkovska I, Pickhardt PJ, Rauch GM, Rosenthal MH, Sheedy SP, Horvat N. Rectal cancer lexicon: consensus statement from the Society of Abdominal Radiology rectal & anal cancer disease-focused panel. Abdom Radiol (NY) 44(11):3508-3517, 2019. e-Pub 2019. PMID: 31388697.
64. Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 26(10):3071-3079, 2019. e-Pub 2019. PMID: 31342361.
65. Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM. Digital breast tomosynthesis for intraoperative margin assessment during breast-conserving surgery. Ann Surg Oncol 26(6):1720-1728, 2019. e-Pub 2019. PMID: 30877499.
66. Adrada B, Rauch GM. Molecular breast imaging in evaluating breast cancer extent of disease. JBI 1(2):155-156, 2019. e-Pub 2019. PMID: None.
67. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol 114(None):167-174, 2019. e-Pub 2019. PMID: 31005169.
68. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal carcinoma in situ and margins <2mm: contemporary outcomes with breast conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
69. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
70. Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. High risk breast lesions identified on MRI-guided vacuum-assisted needle biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol 91(1090):20180300, 2018. e-Pub 2018. PMID: 29947265.
71. Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, Arribas E, Sun J, Leung JWT, Krishnamurthy S, Yang WT. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol 25(7):1953-1960, 2018. e-Pub 2018. PMID: 29667115.
72. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2017. PMID: 28549010.
73. van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg 105(5):535-543, 2018. e-Pub 2018. PMID: 29465744.
74. Parikh AM, Coletta AM, Yu ZH, Rauch GM, Cheung JP, Court LE, Klopp AH. Development and validation of a rapid and robust method to determine visceral adipose tissue volume using computed tomography images. PLoS One 12(8):e0183515, 2017. e-Pub 2017. PMID: 28859115.
75. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):665-670, 2017. e-Pub 2017. PMID: 28423171.
76. Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-concordant benign MRI-guided vacuum-assisted breast biopsy may not warrant MRI follow-up. AJR Am J Roentgenol 208(4):1-7, 2017. e-Pub 2017. PMID: 28140609.
77. Ho JC, Allen PK, Bhosale PR, Rauch GM, Fuller CD, Mohamed AS, Frumovitz M, Jhingran A, Klopp AH. Diffusion-weighted magnetic resonance imaging as a predictor of outcome in cervical cancer after chemoradiation. Int J Radiat Oncol Biol Phys 97(3):546-553, 2017. e-Pub 2016. PMID: 28011045.
78. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of computed tomography- and magnetic resonance imaging-based clinical target volume contours at brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 96(4):793-800, 2016. e-Pub 2016. PMID: 27788952.
79. Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, Caudle AS, Fox PS, Smith BD, Adrada BE, Krishnamurthy S, Yang WT. Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence. Ann Surg Oncol 23(2):482-9, 2016. e-Pub 2015. PMID: 26416712.
80. Swanick CW, Castle KO, Rechner LA, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy 14(3):385-9, 2015. e-Pub 2015. PMID: 25620163.
81. Scoggins ME, Fox PS, Kuerer HM, Rauch GM, Benveniste AP, Park YM, Lari SA, Krishnamurthy S, Yang WT. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. AJR Am J Roentgenol 204(4):878-888, 2015. PMID: 25794082.
82. Adrada BE, Miranda RN, Clemens MW, Rauch GM, Arribas E, Fanale M, Haideri N, Mustafa E, Medeiros LJ, Yang W. Breast implant-associated anaplastic large cell lymphoma: analysis of imaging studies in 44 patients reveals need for systematic assessment of mass versus no mass to improve diagnostic accuracy. Plast Reconstr Surg 134(4S-1):95-96, 2014. PMID: 25254804.
83. Rauch GM, Kaur H, Choi H, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Marcal LP. Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer. Radiographics 34(4):1082-98, 2014. PMID: 25019443.
84. Verma J, Sulman EP, Jhingran A, Tucker SL, Rauch GM, Eifel PJ, Klopp AH. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88(2):357-62, 2014. PMID: 24411609.
85. Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT. Clinicopathologic, mammographic, and sonographic features in 1187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139(3):639-647, 2013. e-Pub 2013. PMID: 23774990.
86. Rauch GM, Dogan BE, Smith TB, Liu P, Yang WT. Outcome analysis of 9-gauge MRI-guided vacuum-assisted core needle breast biopsies. AJR Am J Roentgenol 198(2):292-9, 2012. PMID: 22268171.
87. Meyer JS, Thornby J, Y-S L, Rauch GM. Migraine cluster and chronic daily headaches often accompanied by cognitive decline. John Hopkins University Advanced Studies in Medicine 1:97-100, 2001. PMID: None.
88. Meyer JA, Y-S L, Rauch GM, Haque A. Risk factors for accelerated cerebral degenerative changes and cognitive decline. Research and Practice in Alzheimer's Disease and Other Dementias 5:27-30, 2001. PMID: None.
89. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Headache 40(8):638-646, 2000. PMID: 10971660.
90. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 903(None):411-23, 2000. PMID: 10818532.
91. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment and dementia. Neurobiol Aging 21(2):161-169, 2000. PMID: None.
92. Meyer JS, Rauch GM. Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy. Keio J Med 49 Suppl 1(None):A25-8, 2000. PMID: 10750330.
93. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. XE-CT CBF changes during normative aging, cognitive decline and dementia. Keio J Med 49 Suppl 1(None):A95-7, 2000. PMID: 10750350.
94. Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, Terayama Y, Haque A. Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 14(12):1050-61, 1999. PMID: 10607973.
95. Mortel KF, Meyer JS, Rauch GM, Konno S, Haque A, Rauch RA. Factors influencing survival among patients with vascular dementia and Alzheimer's disease. J Stroke Cerebrovasc Dis 8(2):57-65, 1999. PMID: 17895141.
96. Konno S, Meyer JS, Margishvili GM, Rauch RA, Haque A. Transformed migraine is a cause of chronic daily headaches. Headache 39(2):95-100, 1999. PMID: 15613201.
97. Meyer JS, Konno S, Margishvili GM, Terayama Y. Vasodilator responses to acetazolamide tested in subtypes of vascular dementia. J Stroke Cerebrovasc Dis 7(5):323-329, 1998. PMID: 17895108.
98. Meyer JS, Terayama Y, Konno S, Margishvili GM, Akiyama H, Rauch RA, Mortel KF, Wills PM. Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia 18(None):202-208, 1998. PMID: 9642495.
99. Meyer JS, Terayama Y, Konno S, Akiyama H, Margishvili GM, Motel KF. Risk factors for cerebral degenerative changes and dementia. Eur Neurol 39 Supplement(1):7-16, 1998. PMID: 9516069.
100. Meyer JS, Akiyama H, Konno S, Mortel KF, Margishvili GM. Human aging: risk factors for cerebral atrophy. Ann N Y Acad Sci 826(1):483-489, 1997. PMID: 9329729.
101. Amcheslavski VG, Demchuk ML, Madorski SV, Toma GI, Margishvili GM, Fokin SV, Savin IA. The use of the preparation of Nimotop in neurosurgical patients. Zh Vopr Neirkhir Im N N Burdenko 3:41-43, 1997. PMID: 9424955.
102. Grindel OM, Koptelov YM, Masherov YL, Voronina IA, Margishvili GM. EEG pathological zone localization in patients with brain tumors by BRAINLOC method. Zhurnal Physiologia cheloveka (Journal of Human Physiology) 23:36-45, 1997. PMID: None.
103. Boldyreva GN, Bragina NN, Margishvili GM, Masherov EL. Effect of a stationary focus of excitation in the limbic structures in spatial-temporal organization of the human EEG. Fiziol Cheloveka 21(None):18-28, 1995. PMID: 8566498.
104. Livshits AV, Sokolova AA, Margishvili GM. The dynamic changes in the somatosensory evoked potentials in injury of the spinal and spinal cord trauma after meningomyeloradiculolysis. Zh Vopr Neirokhir Im N N Burdenko 1(None):26-30, 1995. PMID: 7762313.
105. Livshits AV, Sokolova AA, Margishvili GM. Dynamics of somatosensory evoked potentials in patients with spinal tumors. Zhurnal Voprosi Neirochirurgii imeni (Journal Questions of Neurosurgery) 4-5:19-21, 1992. PMID: None.
106. Livshits AV, Sokolova AA, Margishvili MG. The dynamics of somatosensory evoked potentials in patients with a spinal cord tumor. Zh Vopr Neirokhir Im N N Burdenko None(4-5):19-21, 1992. PMID: 1334307.
107. Chen J, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer H, Meas S, Sarli V, Korkut A, White J, Rauch G, Tripathy D, Arun B, Barcenas C, Yam C, Sethi H, Rodriguez A, Liu M, Moulder-Thompson S, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016. PMID: 39148033.
108. Yan Y, Lin Y, Kumar T, Bai S, Thennavan A, Li J, Tran T, Hu M, Rao M, Casasent A, Ravenberg E, Rauch GM, Clayborn A, Tripathy D, Thompson A, Lim B, Huo L, Moulder S, Yam C, Navin N. Decoding the archetypes and ecotypes of triple-negative breast cancer in response to chemotherapy. Cell. PMID: None.

Invited Articles

1. Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating breast surgery for invasive cancer with exceptional response to neoadjuvant systemic therapy: Prospective multicenter clinical trial planned initial feasibility endpoint. J Am Coll Surg 237(1):101-108, 2023. e-Pub 2023. PMID: 36856291.
2. Rauch GM, Adrada BE. Comparison of breast MR imaging with molecular breast imaging in breast cancer screening, diagnosis, staging, and treatment response evaluation. Magn Reson Imaging Clin N Am 26(2):273-280, 2018. PMID: 29622132.
3. Adrada BE, Moseley T, Rauch GM. Molecular breast imaging: role as a screening modality. Curr Breast Cancer Rep 8(4):230-235, 2016. e-Pub 2016. PMID: None.

Manuals, Teaching Aids, Other Teaching Publications

1. Sivucha TA, Kochetova AP, Demin VA, Kossichkin MM, Gilinskaia MI, Rauch GM, Olesik I, Liaschevko VI, Volkov AV. Medical and social rehabilitation of the disabled with benign spinal cord tumors. None, 1992.
2. Sivucha TA, Grinchuk VI, Kossichkin MM, Demin VA, Gilinskaia MI, Gendlina IS, Manukian EA, Oleski I, Rauch GM, Smanov KD, Prianikov IV, Malkumiantz TA, Vershinina AB, Polunina LV, Shpirt EI, Drobashenko TG, Petrova OP. Medical and social rehabilitation of the disabled with compromised cerebral venous circulation. None, 1991.

Other Articles

1. Yankeelov TE, Hormuth DA, EABF L, Lorenzo G, Wu C, Okereke LC, Rauch GM, Venkatesan AM, Chung C Designing clinical trials for patients who are not average. iScience 27(1):108589, 2024. PMID: 38169893.
2. Rauch GM Editorial Comment: Pros and cons of implementation of synoptic reporting in oncologic imaging. AJR Am J Roentgenol 221(6):772, 2023. PMID: 37530401.
3. Patel MM, Adrada BE, Fowler AM, Rauch GM Molecular breast imaging and positron emission mammography. PET Clin 18(4):487-501, 2023. PMID: 37258343.
4. El Homsi M, Sheedy SP, Rauch GM, Ganeshan DM, Ernst RD, Golia Pernicka JS Follow-up imaging of anal cancer after treatment. Abdom Radiol (NY) 48(9):2888-2897, 2023. PMID: 37024606.
5. Paroder V, Fraum TJ, Nougaret S, Petkovska I, Rauch GM, Kaur H Key clinical trials in rectal cancer shaping the current treatment paradigms: reference guide for radiologists. Abdom Radiol (NY) 48(9):2825-2835, 2023. PMID: 37221342.
6. Golia Pernicka JS, Rauch GM, Gangai N, Bates DDB, Ernst R, Hope TA, Horvat N, Sheedy SP, Gollub MJ Imaging of anal squamous cell carcinoma: Survey results and expert opinion from the Rectal and anal cancer disease-focused panel of the Society of Abdominal Radiology. Abdom Radiol (NY) 48(9):3022-3032, 2023. PMID: 36932225.
7. Smith KA, Hunt KN, Rauch GM, Fowler AM Molecular breast imaging in the screening setting. J Breast Imaging 5(3):240-247, 2023. PMID: 38416886.
8. Kaur H, Gabriel H, Taggart M, Kang HC, Konishi T, Rauch GM, Krishnan S, Chang G MRI staging in an evolving management paradigm for rectal cancer, from the AJR Special Series on cancer staging. AJR Am J Roentgenol 217(6):1282-1293, 2021. PMID: 33949877.
9. Rauch GM, Kuerer HM, Jochelson MS To look or not to look? Yes to nodal ultrasound!. J Breast Imaging 3(6):659-665, 2021. PMID: 38424935.
10. Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GM Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185(1):1-12, 2021. PMID: 32920733.
11. Adrada BE, Moseley T, Kappadath SC, Whitman GJ, Rauch GM Molecular breast imaging-guided percutaneous biopsy of breast lesions: a new frontier on breast intervention. J Breast Imaging 2(5):484-491, 2020. PMID: 33015619.
12. Kaur H, Ernst RD, Rauch GM, Harisinghani M Nodal drainage pathways in primary rectal cancer: anatomy of regional and distant nodal spread. Abdom Radiol (NY) 44(11):3527-3535, 2019. PMID: 31628513.
13. Golia Pernicka JS, Sheedy SP, Ernst RD, Minsky BD, Ganeshan D, Rauch GM MR staging of anal cancer: What the radiologist needs to know. Abdom Radiol (NY) 44(11):3726-3739, 2019. PMID: 31041496.
14. Ganeshan D, Nougaret S, Korngold E, Rauch GM, Moreno CC Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol (NY) 44(11):3709-3725, 2019. PMID: 30953096.
15. Venkatesan AM, Menias CO, Jones KM, Rauch GM, Stafford RJ, Klopp AH MRI for radiation therapy planning in human papillomavirus-associated gynecologic cancers. Radiographics 39(5):1476-1500, 2019. PMID: 31498740.
16. Tayyab SJ, Adrada BE, Rauch GM, Yang WT A pictorial review: multimodality imaging of benign and suspicious features of fat necrosis in the breast. Br J Radiol 91(1092):20180213, 2018. PMID: 29987981.
17. Adrada BE, Candelaria R, Rauch GM MRI for the staging and evaluation of response to therapy in breast cancer. Top Magn Reson Imaging 26(5):211-218, 2017. PMID: 28961570.
18. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK DCIS margins and breast conservation: MD Anderson Cancer Center multidisciplinary practice guidelines and outcomes. J Cancer 8(14):2653-2662, 2017. PMID: 28928852.
19. Rauch GM, Adrada BE, Kuerer HM, van la Parra RF, Leung JW, Yang WT Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. AJR Am J Roentgenol 208(2):290-299, 2017. PMID: 27809573.
20. Adrada BE, Miranda RN, Rauch GM, Arribas E, Kanagal-Shamanna R, Clemens MW, Fanale M, Haideri N, Mustafa E, Larrinaga J, Reisman NR, Jaso J, You MJ, Young KH, Medeiros LJ, Yang W Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat 147(1):1-14, 2014. PMID: 25073777.
21. Kaur H, Choi H, You YN, Rauch GM, Jensen CT, Hou P, Chang GJ, Skibber JM, Ernst RD MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics 32(2):389-409, 2012. PMID: 22411939.
22. Meyer JS, Margishvili GM, Konno S Headache associated with metabolic disorders. Neurobase, 1998. PMID: None.
23. Meyer JS, Margishvili GM, Rauch RA, Haque A Late-life migrainous accompaniments. Neurobase, 1998. PMID: None.
24. Meyer JS, Margishvili GM, Rauch RA, Haque A Migrainous infarction. Neurobase, 1998. PMID: None.
25. Konno S, Meyer JS, Terayama Y, Margishvili GM, Mortel KF Classification, diagnosis and treatment of vascular dementia. Drugs Aging 11(None):361-373, 1997. PMID: 9359023.
26. Meyer JS, Margishvili GM, Terayama Y, Konno S Headache associated with arterial hypertension. Neurobase, 1997. PMID: None.

Editorials

1. Rauch GM. Biomarkers for personalized neoadjuvant therapy in triple-negative breast cancer: Moving forward. Radiology 112(3):E242011, 2024. PMID: 39225606.
2. Rauch GM. Precision imaging: One step closer to pretreatment prediction of breast cancer response to neoadjuvant systemic therapy. Radiology 308(1):e231482, 2023. PMID: 37432087.
3. Kuerer HM, Krishnamurthy S, Rauch GM, Yang WT, Smith BD, Valero V. Optimal selection of breast cancer patients for elimination of surgery following neoadjuvant systemic therapy. Ann Surg 268(6):e61-e62, 2018. PMID: 29064904.
4. Rauch GM. ASO Author Reflections: Elimination of breast cancer surgery in complete responders after neoadjuvant chemotherapy: imaging perspective. Ann Surg Oncol 25(Suppl 3):628-629, 2018. PMID: 30244417.
5. Meyer JS, Rauch GM. Gender differences in cerebral perfusion. J Neurol Sci 162(2):113, 1999. PMID: 10202975.
6. Rauch GM. Moving forward with quantitative imaging and tumor biology based biomarkers for personalized neoadjuvant therapy in triple negative breast cancer. Radiology None(None):None. PMID: None.

Abstracts

1. Stowers CE, Wu C, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Predicting the response of triple negative breast cancer to neoadjuvant chemotherapy via biology-based modeling and habitat analysis. San Antonio Breast Cancer Symposium None(None):None. e-Pub 2024. PMID: None.
2. Rauch GM, Moseley T, Guirguis M, Whitman G, Candelaria R, Leung J, Patel M, Sun J, Le-Petross H, Lane D, Scoggins M, Perez F, Mohamed RM, Xu Z, Pashapoor S, Son JB, Hwang KP, Chen H, Wei P, Tripathy D, Yang W, Yam C, Ma J, Adrada B. DCE-MRI tumor volumetric changes predict response to neoadjuvant immunochemotherapy in triple negative breast cancer patients. International Society for Magnetic Resonance in Medicine Annual Meeting, 2024. PMID: None.
3. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Optimizing therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy. Cancer Res 84(9 Supplement):None, 2024. PMID: None.
4. Rauch GM, Guirguis M, Patel M, Candelaria RP, Mohamed R, Moseley T, Le-Petross HT, Leung J, Whitman G, Lane DL, Scoggins M, Perez F, Sun J, Pashapoor S, Xu Z, White J, Wei P, Reed B, Son JB, Hwang KP, Panthi B, Korkut A, Huo L, Hunt KK, Clayborn A, Litton J, Valero V, Tripathy D, Yam C, Yang W, Ma J, Adrada B. Early prediction of response to neoadjuvant immunotherapy in triple negative breast cancer (TNBC) with DCE-MRI. Can Res 84(9 Supplement):None, 2024. PMID: None.
5. Xu Z, Son JB, Adrada BE, Moseley TW, Candelaria RP, Guirguis MS, Patel MM, Whitman GJ, Leung JWT, Le-Petross HTC, Mohamed RM, Pashapoor S, Lane DL, Perez F, Chen H, Sun J, Wei P, Tripathy D, Yang W, Yam C, Rauch GM, Ma J. Deep learning models for predicting responses to neoadjuvant systemic therapy in triple-negative breast cancer using pre-treatment MRI. International Society for Magnetic Resonance in Medicine Annual Meeting, 2024. PMID: None.
6. Stowers CE, Wu C, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy. Cancer Res 84(9 Supplement):None, 2024. PMID: None.
7. Hwang KP, Son JB, Xu Z, Mohamed R, Chen H, Adrada BE, Mosley T, Yam C, Wei P, Yang W, Ma J, Rauch GM. Prediction of neoadjuvant systemic treatment response in triple-negative breast cancer using a 3D neural network on synthetic MR images. International Society for Magnetic Resonance in Medicine Annual Meeting, 2024. PMID: None.
8. Moseley T, Chung H, Patel M, Adrada B, Zylberman G, Bragner J, Arun B, Bevers T, Rauch GM. Comparative performance of Molecular Breast Imaging (MBI) and Magnetic Resonance Imaging (MRI) for annual surveillance of women at high risk for breast cancer. European Society of Breast Imaging None(None):None. e-Pub 2024. PMID: None.
9. Mohamed RM, Son JB, Adrada B, Moseley T, Whitman G, Candelaria R, Panthi B, Chen H, Guirguis M, Leung J, Hwang KP, Pashapoor S, Patel M, Scoggins M, Le-Petross H, Lane D, Perez F, Wei P, Xu Z, Tripathy D, Yang W, Yam C, Ma J, Rauch GM. Radiomics and background parenchymal enhancement of fibroglandular tissue for predicting treatment response in triple-negative breast cancer. International Society for Magnetic Resonance in Medicine Annual Meeting, 2024. PMID: None.
10. Patel RJS, Wu C, Stowers CE, Mohamed RM, Ma J, Rauch GM, Yankeelov TE. Predicting the response of I-SPY 2 breast cancer patients to treatment using a biology-based mathematical model calibrated with quantitative MRI. International Society for Magnetic Resonance in Medicine Annual Meeting, 2024. PMID: None.
11. Valero V, Mouabbi J, Alonzo H, Pohlmann P, Nwosu-Iheme A, Hassan A, Murthy R, Huang X, Qiao W, Patel M, Rauch GM, Checka C, Symmans F, Hunt K, Tripathy D, Meric-Bernstam F. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer. Cancer Res 84(9 Supplement):None, 2024. PMID: None.
12. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Bon JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Integrating mechanism-based modeling and MRI data to improve predictions of breast cancer response to chemotherapy. Society of Mathematical Biology Annual Meeting None(None):None. e-Pub 2024. PMID: None.
13. Stowers, CE, Wu, C, Lorenzo, G, Xu, Z, Ma, J, Rauch, GM, Yankeelov, TE. Mechanically-coupled, biology-informed modeling for predicting triple-negative breast cancer response to neoadjuvant therapy. WCCM None(None):None. e-Pub 2024. PMID: None.
14. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Patient-specific optimization of therapeutic regimens via digital twins to improve triple negative breast cancer response to neoadjuvant therapy. WCCM None(None):None. e-Pub 2024. PMID: None.
15. Wu C, Stowers CE, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamie JI, Rauch GM, Yankeelov TE, EABF L. Patient-specific digital twins to predict TNBC response to NAT via hybrid modeling and data assimilation. Joint Center for Computational Oncology - 4th Annual Research Retreat, 2023. PMID: None.
16. Wu C, Stowers CE, Kumar S, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE, EABR L. Developing MRI-based digital-twins via hybrid modeling and data assimiliation to predict triple-negative breast cancer response to neoadjuvant chemotherapy. Joint Center for Computational Oncology - 4th Annual Research Retreat, 2023. PMID: None.
17. Johnson HM, Smith BD, Rauch GM, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Moseley TW, Leung JWT, Huang M, Candelaria RP, Adrada BE, Arribas E, la Parra RFD, Hung KK, Bedrosian I, Teshome M, Sun SX, Hwang RF, Miggins MV, Piotrowski M, Refinetti AP, Ehlers RA, Colen JS, Loveland-Jones C, Lesnikowski BA, Samiian L, Chong C, Shaitelman SF, Mitchell MP, Kuerer HM. Eliminating breast surgery for invasive cancer following neoadjuvant systemic therapy (NST): Prospective multicenter clinical trial first planned feasibility report. Western Surgical Association, 2023. PMID: None.
18. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Forecasting response to neoadjuvant systemic therapy in triple-negative breast cancer for personalized medicine via mathematical modeling and quantitative MR imaging. Joint Center for Computational Oncology - 4th Annual Research Retreat, 2023. PMID: None.
19. Christenson C, Wu C, Hormuth II DA, Pash G, Stowers C, LaMonica M, Wilcox K, Ma J, Rauch GM, Yankeelov TE. Introducing mechanical stress into a reduced order model for breast cancer response to chemotherapy. BMES Annual Meeting None(None):None. e-Pub 2023. PMID: None.
20. Kuerer HM, Rauch GM, Krishnamurthy S, Diego EJ, Yang WT, Shen Y, Lin H, Lucci A, Ramirez DL, Moseley TW, Mouabbi JA, Boughey JC, Shaitelman SF, White RL, Hunt KH, Mitchell MP, Teshome MT, Johnson HM, Smith BD, Valero V. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial. ESMO 34(Supplement 2):S280, 2023. PMID: None.
21. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc 2023:1-4, 2023. PMID: 38083160.
22. Wu C, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE, EABF L. Optimization of a longitudinal imaging protocol to monitor the response of breast cancer to neoadjuvant therapy via Bayesian-based data assimilation. Society of Mathematical Biology Annual Meeting, 2023. PMID: None.
23. Wu C, EABF L, Stowers CE, Xu Z, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Optimization of longitudinal imaging protocol to monitor triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy via Bayesian-based data assimilation. Society for Mathematical Biology Annual Meeting, 2023. PMID: None.
24. Lopez BP, Rauch GM, Kappadath SC. Absolute 99mTc-Sestamibi breast uptake in HER2-, HER2+, and TNBC patients undergoing neoadjuvant chemotherapy. American Association of Physicists in Medicine None(None):None, 2023. PMID: None.
25. Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross H, Leung JWL, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White JB, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GM. Early prediction of response to neoadjuvant systemic therapy of triple negative breast cancer using radiomics on DCE-MRI. ISMRM & ISMRT 2023 Annual Meeting, 2023. PMID: None.
26. Kumar T, Lin Y, Yan Y, Bai S, Li J, Tran T, Hu M, Ravenberg E, Rauch M, Clayborn A, Thompson A, Huo L, Moulder S, Yam C, Navin N. Decoding the natural biology of triple-negative breast cancer and response to chemotherapy by single-cell transcriptomics. Cancer Res 83(7), 2023. PMID: None.
27. Patel RJS, Wu C, Stowers CE, Mohammed RMM, Kasprick TS, Rauch GM, Yankeelov TE. Predicting the response of I-SPY 2 breast cancer patients to treatment using a mechanism-based model and quantitative MRI data. Mathematical Oncology, 2023. PMID: None.
28. Stowers CE, Wu C, Kumar S, EABF L, Xu Z, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy. Cancer Res 83(7 Supplement):None, 2023. PMID: None.
29. Xu Z, Pashapoor S, Panthi B, Son JB, Hwang KP, Adrada BE, Candelaria RP, Guirguis MS, Patel MM, Le-Petross H, Leung J, Scoggins ME, Whitman G, Mohamed R, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt K, Moulder S, Litton J, Valero V, Tripathy D, Yang W, Yam C, Rauch GM, Ma J. Tumor segmentation with nnU-Net on dynamic contrast enhanced MR images of triple negative breast cancer. ISMRM & ISMRT 2023 Annual Meeting. e-Pub 2023. PMID: None.
30. Wu C, Jarrett AM, Zhou Z, Ma J, Rauch GM, Yankeelov TE. Forecasting patient-specific treatment response to neoadjuvant chemotherapy in triple-negative breast cancer via MRI-based digital twins. NCI Junior Investigator Meeting. e-Pub 2023. PMID: None.
31. Wu C, Stowers C, Jarrett AM, Zhou Z, Ma J, Rauch GM, Yankeelov TE. MRI-based digital twins forecast patient-specific treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer. International Society for Magnetic Resonance in Medicine Annual Meeting. e-Pub 2023. PMID: None.
32. Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Zu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathu D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma J. Deep learning models for automatic segmentation of triple negative breast cancer (TNBC). 45th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. e-Pub 2023. PMID: None.
33. Zandbergen CAW, Han S, Nevozhay D, Meyer JM, Rauch GM, Cook J, Sokolov K, Bouchard RR. Noninvasive quantitation of EGFR-targeted PAtrace with photoacoustic imaging to assess treatment response in a preclinical model of breast cancer. International Ultrasonics Symposium, 2022. PMID: None.
34. Moseley T, Kapoor MM, Arribas E, Hongying H, Nia ES, Rauch GM, Posleman M, Flavia E. A case of mistaken identity: Differentiating benign and malignant lymph nodes in breast cancer patients in the setting of COVID-19. NCoBC - 31st Annual Interdisciplinary Breast Center Conference, 2022. PMID: None.
35. Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed R, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. Image-informed mathematical modeling to predict patient-specific treatment response to neoadjuvant systemic therapy in triple negative breast cancer. Seventh Computational Approaches for Cancers Workshop, 2021. PMID: None.
36. Abuhadra N, Thompson A, Mittendorf E, Litton J, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Symmans WF, Huo L, White JB, Ravenberg, EE, Sun R, Lim B, Moulder-Thompson S, Yam C, Tripathy D. Computed Response Score (CRS): An integrated approach to pathologic complete response (pCR) prediction in early-stage triple-negative breast cancer (TNBC) with high stromal tumor infiltrating lymphocytes (sTIL). ASCO. e-Pub 2021. PMID: None.
37. Lopez BP, Rauch GM, Kappadath SC. Automating tumor functional diameter measurement with molecular breast imaging for treatment response assessment. Med Phys 48(6):E168, 2021. PMID: None.
38. Zhou Z, Rauch DE, Son JB, Musall BC, Elshafeey NA, White JB, Pagel MD, Moulder S, Ma J, Rauch GM. Early prediction of pathologic complete response to neoadjuvant systemic therapy for triple-negative breast cancer using deep learning. International Society for Magnetic Resonance in Medicine - Virtual, 2021. PMID: None.
39. Slavkova KP, DiCarlo JC, Wadhwa V, Ma J, Rauch GM, Zhou Z, Yankeelov TE. Implementing ConvDecoder with physics-based regularization to reconstruct under-sampled variable-flip angle MRI data of the breast. International Society for Magnetic Resonance in Medicine - Virtual, 2021. PMID: None.
40. Elshafeey NA, Rauch GM, Kotrotsou A, Adrada A, Candelaria RP, Abdelhafez AH, Chen H, Sun J, Boge M, Mohamed RM, Musall BC, Son JB, Zhang S, White JB, Willis B, Ravenberg E, Pen W, Moulder SL, Yang W, Pagel MD, Ma J, Hwang KP. Radiomics model based on MAGIC acquisition for predicting neoadjuvant systemic treatment response in triple-negative breast cancer. International Society for Magnetic Resonance in Medicine - Virtual, 2021. PMID: None.
41. Guirguis MS, Adrada BE, Le-Petross H, Dryden MJ, Rauch GM, Whitman GJ, Moseley T. Preoperative bracketing of multifocal breast carcinoma: a multimodality approach. Society of Breast Imaging Symposium, 2021. PMID: None.
42. Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, Cho N, Teoh V, Rauch GM, Smith BD, Valero V, Mohammed K, Han W, MacNeill F, Kuerer HM. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg 155(12):e204103, 2020. e-Pub 2020. PMID: 33026457.
43. Elshafeey NA, Adrada BE, Kotrotsou A, Abdelhafez AH, Candelaria RP, Yang WT, Sun J, Mohamed R, Boge M, Mahmoud H, Musall B, Son JB, Tripathy D, Santiago L, Thompson A, Valero V, Whitman G, Litton J, Lim B, Le-Petross HC, Leung JT, Lane D, Arribas E, Spak D, Scoggins M, Moseley T, Ueno N, Zhang S, White J, Moulder S, Hwang KP, Wei P, Pagel M, Ma, Rauch GM. Radiomic phenotypes from ultrafast dynamic contrast enhanced (DCE) MRI for prediction of the treatment response to neoadjuvant systemic therapy (NAST) of triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
44. Rauch GM, Adrada BE, Candelaria RP, Elshafeey NA, Mohamed RM, Boge M, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Spak D, Valero V, Litton J, Huo L, Tripathy D, Mittendorf E, Thompson A, Arribas E, Scoggins M, Musall B, Kotrotsou A, Sun J, Son JB, White J, Zhang S, Hwang KP, Wei P, Moulder S, Pagel M, Ma J, Yang WT. Longitudinal MR imaging findings in triple negative breast cancer (TNBC) patients undergoing neoadjuvant systemic therapy (NAST) stratified by tumor infiltrating lymphocytes (TIL) levels. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
45. Pagel MD, Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed RM, Hamed A, Son JB, Sun J, Elshafeey NA, White JB, Musall BC, Miyoshi M, Wang X, Wei P, Hwang KP, Ma J. Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC). Chemical Exchange Saturation Transfer Imaging 2020 Annual Meeting - Virtual, 2020. PMID: None.
46. Kotrotsou A, Elshafeey NA, Adrada BE, Sun J, Candelaria RP, Abdelhafez AH, Yang WT, Mohamed R, Boge M, Willis B, Musall B, Son JB, Zhang S, Thompson A, Tripathy D, Moseley T, Litton J, Whitman G, Le-Petross HC, Valero V, Santiago L, Lane D, Lim B, Leung JT, Scoggins M, Spak D, Arribas E, White J, Ravenberg E, Cardenas-Rodriguez J, Wei P, Moulder S, Rauch GM, Pagel M. Reliability of pharmacokinetic (PK) parameters by DCE-MRI for prediction of neoadjuvant systemic treatment (NAST) response in triple negative breast cancer (TNBC) patients: a comparison of three analysis methods. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
47. Zhang S, Rauch GM, Adrada BE, Abdelhafez AH, Son J, Yang WT, Sun J, Boge M, Mohamed R, Elshafeey N, White J, Musall B, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Miyoshi M, Wang X, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Candelaria RP, Moulder S, Ma J, Pagel M. Comparison of chemical exchange saturation transfer (CEST) MRI acquisition and analysis for early neoadjuvant systemic therapy (NAST) treatment response assessment in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
48. Musall B, Abdelhafez AH, Adrada BE, Jon J, Candelaria RP, Sun J, Yang WT, Santiago L, Whitman G, Le-Petross HC, Moseley T, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Mahmoud H, White J, Hwang KP, Elshafeey N, Mohamed R, Boge M, Kotrotsou A, Zhang S, Damodaran S, Litton J, Valero V, Tripathy D, Thompson A, Wei P, Moulder S, Pagel M, Ma J, Rauch GM. Radiomic features of quantitative apparent diffusion coefficient (ADC) maps from peritumoral regions (PTRs) as predictors of early treatment response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
49. Vasaikar S, Seth S, Hollander PD, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Damodaran S, White J, Tripathi D, Piwnica-Worms H, Symmans WF, Chang J, Mani S, Moulder SL. Assessment of mid-neoadjuvant chemotherapy (NACT) biopsies identifies two potential gene signatures that predict for 2 year recurrence free survival (RFS-2) in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium - Virtual, 2020. PMID: None.
50. Zhang S, Rauch GM, Adrada BE, Boge M, Mohamed R, Yang WT, Elshafeey N, Sun J, Abdelhafez A, Son JB, White J, Moseley T, Whitman G, Le-Petross HC, Santiago L, Lane D, Leung JT, Scoggins M, Spak D, Arribas E, Ravenberg E, Musall B, Miyoshi M, Wang Z, Willis B, Hash S, Kotrotsou A, Wei P, Hwang KP, Litton J, Thompson A, Moulder S, Candelaria R, Ma J, Pagel M. Assessment of early response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: pilot study. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
51. Hwang KP, Vikram R, Ernst R, Rauch G, Devine C, Ma J, Kaur H. Quality improvement and troubleshooting in rectal MRI - how we do it. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
52. Guirguis M, Adrada B, Le-Petross HC, Dryden M, Rauch G, Moseley T, Whitman G. Challenging cases in breast localization: a multimodality approach. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
53. Candelaria RP, Adrada BE, Lane DL, Bassett R, Santiago L, Rauch GM, Moseley T, Scoggins M, Thompson A, Ravenberg E, White J, Spak D, Le-Petross HC, Arribas E, Whitman G, Leung JT, Litton J, Mittendorf E, Huo L, Valero V, Moulder S, Yang WT. BI-RADS ultrasound lexicon descriptors and tumor-infiltrating lymphocytes in triple negative breast cancer. Virtual - Radiological Society of North America Annual Meeting, 2020. PMID: None.
54. Zhang S, Abdelhafez AH, Son JB, Musall BC, Miyoshi M, Wang Z, Hwang KP, Rauch GM, Ma J, Pagel MD. Tumor response to neoadjuvant chemotherapy in triple negative breast cancer using CEST MRI. International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. PMID: None.
55. Hwang KP, Wang X, Ernst RD, Palmquist SM, Level M, Rauch GM, Chang GJ, Messick C, Taggart MW, Bayram E, Ma J, Kaur H. Deep learning based image reconstruction for T2-weighted rectal cancer imaging. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. PMID: None.
56. Son JB, Hwang KP, Scoggins ME, Basek ED, Rauch GM, Pagel MD, Ma J. Semi-supervised image domain transfer for Dixon water and fat separation. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. PMID: None.
57. Zhang S, Abdelhafez AH, Son JB, Musall B, Miyoshi M, Wang X, Hwang KP, Rauch GM, Ma J, Pagel M. Optimized CEST acquisition and analysis for treatment assessment of response to neoadjuvant chemotherapy in triple-negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. PMID: None.
58. Musall BC, Abdelhafez AH, Mahmoud HS, Hwang KP, Son JB, Pagel MD, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Candelaria RP, Helgason T, Ravenberg EE, Litton JK, Moulder SL, Yang WT, Ma J, Rauch GM, Adrada BE. Diffusion fractional anisotropy in peritumoral edema of triple negative breast cancer. 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. PMID: None.
59. Jimenez J, Abeer A, Elshafeey N, Yung J, Hazle J, Rauch G. Quantitative MR imaging features associated with pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. American Association of Physicists in Medicine / Canadian Organization of Medical Physicists Annual Meeting, 2020. PMID: None.
60. Tayyab S, Le-Petross H, Adrada BE, Rauch GM, Moseley T, Sun J, Masood AR. Stromal fibrosis on MRI biopsy: a histopathologic correlation and outcome data. European Congress of Radiology, 2020. PMID: None.
61. Son JB, Hwang KP, Scoggins ME, Dogan BE, Rauch GM, Pagel MD, MaJ. Water and fat separation with a Dixon Conditional Generative Adversarial Network (DixonCGAN). 28th International Society for Magnetic Resonance in Medicine Annual Meeting, 2020. e-Pub 2020. PMID: None.
62. Rauch GM, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins M, Spak D, Leung JWT, Damodaran S, Lim B, Valero V, White J, Thompson AM, Litton JK, Huo L, Moulder SL, Ma J, Yang WT, Adrada BE. Radiomics of quantitative apparent diffusion coefficient (ADC) from fibroglandular tissue (FGT) for prediction of tumor infiltrating lymphocytes (TIL) levels and neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium. e-Pub 2019. PMID: None.
63. Tasoulis MK, Lee HB, MacNeill L, Kuerer HM, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: a multi-institutional pooled analysis. American Society of Clinical Oncology Annual Meeting, 2019. PMID: None.
64. Hwang KP, Son JB, Banerjee S, Zhang T, Ma J, Rauch GM, Warntjes M. 3D multi-parameter mapping of the breast with Dixon fat-water separation. International Society for Magnetic Resonance in Medicine Annual Meeting. e-Pub 2019. PMID: None.
65. Seth S, Huo L, Gilcrease M, Lau R, Piwnica-Worms H, Adrada B, Rauch G, Draetta G, Futreal A, Symmans WF, Moulder S, Chang J. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). EJC 103S1:E129. e-Pub 2018. PMID: None.
66. Scoggins M, Rauch G, Candelaria R, Arribas E, Santiago L, Adrada B. Axillary lymphadenopathy on screening mammography: a first sign of hidden danger?. American Roentgen Ray Society Annual Meeting, 2018. PMID: None.
67. Scoggins M, Santiago L, Arribas E, Rauch G, Lane D, Adrada B. A sheep in wolf's clothing: imaging assessment of multiple intraductal breast papillomas. American Roentgen Ray Society Annual Meeting, 2018. PMID: None.
68. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci Jr A, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Imaging and imaging-guided biopsy assessment of pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017. PMID: None.
69. Son JB, Rauch GM, Hwang KP, Ma J. An automated single-scan Z-spectrum analysis method for amide proton transfer imaging. 39th Annual International Conference of the IEEE Engineering in Medicine & Biology Society, 2017. PMID: None.
70. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Jr LA, Caudle AS, DeSnyder SM, Teshome M, Barcenas C, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients and rationale for elimination of axillary surgery with documented pathologic complete response in the breast after neoadjuvant chemotherapy. Society of Surgical Oncology, 2017. PMID: None.
71. Echeverria GV, Chang JT, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch GM, Adrada BE, Jennifer L, Moulder SL, Symmans WF, Piwnica-Worms H. An annotated collection of pre- and post-therapy breast cancer patient-derived xenoggraft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment. Cancer Res 77(4), 2017. PMID: None.
72. Rauch GM, Adrada BE, Kappadath C, Ma J, Muller F, Moulder S, Yang W. In vivo molecular breast imaging with Tc 99m sestamibi for the prediction of multidrug resistance in triple negative breast cancers. None, 2017. PMID: None.
73. Arribas E, Huang M, Adrada BE, Rauch GM, Santiago L. The atypical malignant axillary lymph node in breast cancer patients. AJR Am J Roentgenol, 2017. PMID: None.
74. Lopez B, Rauch GM, Adrada BE, Bache S, Hess K, Kappadath SC. Quantifying Tc-99msestamibi uptake in breast tumors using molecular breast imaging. Med Phys 44(6):3263, 2017. PMID: None.
75. Moseley TW, Adrada BE, Rauch GM. Molecular breast imaging. Cancer Study and Therapy Conference, 2017. e-Pub 2017. PMID: None.
76. Lopez B, Rauch M, Adrada B, Backe S, Hess K, Kappadath S. Quantification of in Vivo tumor uptake in clinical molecular breast imaging (MBI) examinations. Med Phys 44(6):3263, 2017. PMID: None.
77. Swanick CW, Castle KO, Vedam S, Munsell MF, Turner LM, Rauch GM, Jhingran A, Eifel PJ, Klopp AH. Comparison of CT- and MRI-based clinical target volume contours at the time of brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 93(3):E282, 2016. e-Pub 2016. PMID: None.
78. Rauch GM, Tamm EP, Bhosale PR, Devine C, Rao-Korivi B, Szklaruk J. Dual energy CT for evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer. None, 2016. PMID: None.
79. Shin K, Adrada BE, Rauch GM, Benveniste AP, Yang WT. American Joint Committee on Cancer (AJCC) Breast cancer staging - Multimodality regional nodal basin imaging. None, 2015. PMID: None.
80. Ho J, Allen P, Bhosale P, Rauch G, Fuller C, Mohamed A, Fruimovitz M, Jhingran A, Eifel P, Klopp A. Functional imaging predictors of outcome in cervical cancer following chemoradiation. Int J Radiat Oncol Biol Phys 93(3):E289, 2015. PMID: None.
81. Rauch GM, Tamm E, Bhosale P Devine C, Rao-Korivi B, Szklaruk J. Evaluation of vascular anatomy in patients with hepatobiliary and pancreatic cancer by dual energy CT imaging. Society of Computed Body Tomography & Magnetic Resonance, 2015. PMID: None.
82. Bache S, Adrada B, Jessop A, Rauch G, Kappadath S. Scatter and attenuation correction approaches for quantitative molecular breast imaging. J Nucl Med 56(3):45, 2015. PMID: None.
83. Rauch GM, Ernst R, Marcal LP, You NY, Chang GJ, Rodriguez-Bigas M, Choi H, Kaur H. High-resolution MRI in the presurgical evaluation of low rectal tumors. American Roentgen Ray Society Annual Meeting, 2013. PMID: None.
84. Rauch GM, Marcal LP, Ernst RD, Klopp AH, Boonsirikamchai P, Westin SN, Choi H, Kaur H. High resolution multiplanar MR imaging for pretreatment staging of cervical and endometrial cancer. Society of Computed Body Tomography & Magnetic Resonance, 2012. PMID: None.
85. Meyer JS, Rauch GM. Before thrombolytic therapy for acute stroke xenon inhalation contrast CT CBF imaging is recommended. Stroke: Abstracts from the 4th World Stroke Congress 31(11):2838, 2000. PMID: None.
86. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors for mild cognitive decline and dementia of the vascular and Alzheimer's types. Stroke A Journal of the American Heart Association 31:319, 2000. PMID: None.
87. Meyer JS, Thornby K, Crawford K, Rauch GM, Li Y. Migraine and cluster headaches cause temporary cognitive impairments. Cephalalgia 20:381-382, 2000. PMID: None.
88. Meyer JS, Thornby J, Crawford K, Rauch GM. Reversible cognitive decline accompanies migraine and cluster headaches. Ann Neurol:41, 2000. PMID: None.
89. Meyer JS, Terayama Y, Konno S, Akiyama H, Mortel KF, Margishvili GM. Aging and risk factors for cognitive declines. Ann Neurol 42(3):399, 1997. PMID: None.
90. Meyer JS, Terayama Y, Akiyama H, Konno S, Mortel KF, Margishvili GM, Wills PM. Development of cerebrovascular disease alters the course and symptoms of migraine. Headache 37(5):323, 1997. PMID: None.
91. Meyer JS, Akiyama H, Terayama Y, Konno S, Mortel KF, Margishvili GM. Classification of the vascular dementias validated. J Stroke Cerebrovasc Dis(6):452, 1997. PMID: None.
92. Meyer JS, Akiyama H, Mortel KF, Konno S, Margishvili GM. Risk factors in cerebral atrophy during human aging. Neurology A(48):206, 1997. PMID: None.
93. Meyer JS, Akiyama H, Terayama Y, Mortel KF, Konno S, Margishvili GM. Cerebral degenerative changes during aging with cognitive declines. J Stroke Cerebrovasc Dis 6:439, 1997. PMID: None.
94. Margishvili GM, Amcheslavski VG, Shimanski VN. TCD Evaluation of cerebral blood flow in patients with tumors involving the cavernous sinus before and after surgery. Cerebrovasc Dis:8, 1996. PMID: None.
95. Xu Z, Son JB, Mohamed RM, Adrada B, Wei P, Yam C, Rauch GM, Ma J. SegTNBC: A refined "segment anything (SAM)" model for MR images of triple-negative breast cancer. EMBC 2024 None(None):None. PMID: None.
96. Stowers CE, Wu C, Lorenzo G, Xu Z, Ma J, Rauch GM, Yankeelov TE. Improved mechanically coupled, mechanism-based model for predicting breast cancer response to therapy. World Congress on Computational Mechanics 2024 None(None):None. PMID: None.
97. Stowers C, We C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir J, Rauch GM, Yankeelov T. Integrating biology-based and data-driven modeling for pre-treatment predictions of breast cancer response to therapy. AI in Health Conference None(None):None. PMID: None.
98. Patel RJS, Wu C, Stowers CE, Mohamed RM, Ma J, Rauch GM, Yankeelov TE. Using MRI-based mathematical modeling to predict the response of breast cancer to neoadjuvant therapy. Biomedical Engineering Society None(None):None. PMID: None.
99. Patel RJ, Wu C, Stowers CE, Mohamed RM, Ma J, Rauch GM, Yankeelov TE. Using a mechanism-based mathematical model and multiparametric MRI to predict response to therapy of I-SPY 2 breast cancer patients. Computational Approaches for Cancer Workshop None(None):None. PMID: None.
100. Stowers CE, Wu C, Xu Z, Kumar S, Yam C, Son JB, Ma J, Tamir JI, Rauch GM, Yankeelov TE. Using pre-treatment MRI data to drive an integrated mechanism- and data-driven model to predict the response of breast cancer to therapy. SIAM Imaging Science None(None):None. PMID: None.
101. Wu C, Stowers CE, Kumar S, Tamir JI, Patel RJS, Mohammed RMM, Rauch GM, Yankeelov TE. MRI-based digital twins to forecast treatment response in breast cancer patients. NCI CIRP Annual Virtual Meeting 2023. PMID: None.
102. Patel RJS, Wu C, Stowers CE, Mohammed RMM, Ma J, Rauch GM, Yankeelov TE. Predicting the response of locally advanced breast cancer to neoadjuvant therapy using MRI-based mathematical modeling of the I-SPY 2 dataset. San Antonio Breast Cancer Symposium None(None):None. PMID: None.
103. Rauch G, Kuerer H, Adrada B, Yang W, Guirguis M, Patel M, Arribas E, Kapoor M, Nia E, Moseley T. Less is more: De-escalation of surgery in the breast and axilla - the role of imaging. Radiological Society of North America None(None):None. PMID: None.

Book Chapters

1. Rauch GM, Guirguis MS, Adrada BE. After breast conservation therapy. In: CORE Requisites: Breast Imaging. 4th. Elsevier, 212-232, 2022.
2. Guo C, Bhosale PR, Rauch GM, Matamoros A, Menias C, Schmeler KM, Iyer RB, Venkatesan AM. Tumors of the uterine corpus. In: Oncologic Imaging: A Multidisciplinary Approach. 2nd. Elsevier, 414-437, 2022.
3. Rauch GM, Meyer JS. Estrogen therapy for prevention of dementia in post-menopausal women. In: Vascular Dementia. None. Futura Publishing Company, 2001.
4. Rauch GM, Meyer JS. Clinical features of patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. None. Futura Publishing Company, 2001.
5. Haque A, Meyer JS, Rauch GM. Neuropsychological assessments for cognitive decline. In: Vascular Dementia. None. Futura Publishing Company, 2001.
6. Haque A, Meyer JS, Rauch GM. Epidemiology of vascular dementia. In: Vascular Dementia. None. Futura Publishing Company, 1-8, 2001.
7. Loeb C, Meyer JS, Rauch GM. Criteria for diagnosis of vascular dementia. In: Vascular Dementia. None. Futura Publishing Company, 2001.
8. Meyer JS, Rauch GM, Rauch RA. Neuroimaging in vascular dementia. In: Vascular Dementia. None. Futura Publishing Company, 2001.
9. Meyer JS, Rauch GM. Prevention and treatment of vascular dementia. In: Vascular Dementia. None. Futura Publishing Company, 2001.
10. Meyer JS, Rauch GM. Cardiovascular risk factors contributing to cerebral degenerative changes, cognitive decline, and dementia. In: Vascular Dementia. None. Futura Publishing Company, 19-39, 2001.
11. Meyer JS, Rauch GM. Factors influencing long-term survival among patients with vascular dementia versus Alzheimer's disease. In: Vascular Dementia. None. Futura Publishing Company, 2001.
12. Meyer JS, Rauch GM. Classification of subtypes of vascular dementia including subcortical versus cortical dementias. In: Vascular Dementia. None. Futura Publishing Company, 2001.
13. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors contributing to dementias of vascular and Alzheimer types. In: Proceedings of the 1st International Congress on Vascular Dementia. None. None, 67-70, 1999.
14. Meyer JS, Rauch GM, Rauch RA, Haque A. Risk factors of cerebral hypoperfusion, cognitive decline, and dementia. In: Hemodynamics and cerebral perfusion: new evidence in the pathology of Alzheimer's Disease. None. None, 1999.
15. Meyer JS, Rauch GM, Haque A, Rauch RA. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. In: Vascular Factors in Alzheimer's Disease. None. Cambridge, 1, 1999.

Books (edited and written)

1. Meyer JS, Rauch GM, Lechner H, Loeb C, Toole JF. Vascular dementia. Ed(s) None. Futura Publishing Company, 2001.

Letters to the Editor

1. Kuerer HM, Krishnamurthy S, Rauch GM, Smith B, Valero V, Yang W. Response: Vacuum-assisted biopsy to diagnose a pathological complete response in breast cancer patients after neoadjuvant systemic therapy. Ann Surg, 2017.